Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
29.55
+0.07 (0.22%)
Feb 11, 2026, 2:14 PM EST - Market open
Forte Biosciences Employees
Forte Biosciences had 16 employees as of September 30, 2025. The number of employees increased by 5 or 45.45% compared to the same quarter last year.
Employees
16
Change
5
Growth
45.45%
Revenue / Employee
n/a
Profits / Employee
-$3,233,875
Market Cap
526.83M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 16 | 5 | 45.45% |
| Jun 30, 2025 | 17 | 6 | 54.55% |
| Mar 31, 2025 | 14 | 3 | 27.27% |
| Dec 31, 2024 | 14 | 5 | 55.56% |
| Sep 30, 2024 | 11 | 2 | 22.22% |
| Jun 30, 2024 | 11 | 4 | 57.14% |
| Mar 31, 2024 | 11 | 4 | 57.14% |
| Dec 31, 2023 | 9 | 3 | 50.00% |
| Sep 30, 2023 | 9 | 3 | 50.00% |
| Jun 30, 2023 | 7 | 1 | 16.67% |
| Mar 31, 2023 | 7 | 2 | 40.00% |
| Dec 31, 2022 | 6 | 1 | 20.00% |
| Sep 30, 2022 | 6 | -4 | -40.00% |
| Jun 30, 2022 | 6 | -4 | -40.00% |
| Mar 31, 2022 | 5 | -4 | -44.44% |
| Dec 31, 2021 | 5 | -4 | -44.44% |
| Jun 30, 2021 | 10 | 5 | 100.00% |
| Mar 31, 2021 | 9 | 8 | 800.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 834 |
| Lyell Immunopharma | 300 |
| Gossamer Bio | 145 |
| Lexicon Pharmaceuticals | 103 |
| Solid Biosciences | 100 |
| Neumora Therapeutics | 95 |
| Keros Therapeutics | 82 |
| Lexeo Therapeutics | 61 |
FBRX News
- 1 day ago - Forte Biosciences, Inc. to Present at Upcoming Investor Meetings - Business Wire
- 7 weeks ago - Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - Business Wire
- 3 months ago - Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update - Business Wire
- 3 months ago - Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences - Business Wire
- 4 months ago - Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules - Business Wire
- 5 months ago - Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium - Business Wire
- 6 months ago - Forte Biosciences, Inc. Announces Results and Provides Update - Business Wire
- 8 months ago - Forte Biosciences Announces Pricing of $75 Million Public Offering - Business Wire